Email this article CLINICAL SIGNIFICANCE OF THE VEGFR-2 IN THE TUMORS AND BLOOD SERA OF THE BREAST CANCER PATIENTS
- Authors: Kim E.A.1, Platova A.M.2, Visotzkaya I.V.1, Gershteyn E.S.2, Letyagin V.P.2, Kushlinskiy N.E.2, Mironova E.E.2
-
Affiliations:
- I.M. Sechenov Moscow Medical Academy
- Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences
- Issue: No 1 (2008)
- Pages: 28-32
- Section: MAMMOLOGY. NEW TECHNOLOGIES
- Published: 15.02.2008
- URL: https://ojrs.abvpress.ru/ojrs/article/view/334
- DOI: https://doi.org/10.17650/1994-4098-2008-0-1-28-32
- ID: 334
Cite item
Full Text
Abstract
The analysis of the changes of the content of the angiogenic factor VEGFR-2 in the cytosol of the tumor and blood sera of the 30 breast can- cer patients determined by immunoenzyme method during neoadjuvant therapy is given. Likewise the correlation of this index with the main clinicomorphological characteristics of the disease is assessed. The obtained results suggest on the possibility of the use of VEGFR-2 as the one of the diagnostic markers of the breast cancer. The index dynamics didn’t depend on the given therapy type but nonetheless the correlation of the VEGFR-2 content in the residual tumor after preoperative therapy with the grade of the treatment pathomorphosis is determined.
About the authors
E. A. Kim
I.M. Sechenov Moscow Medical Academy
Author for correspondence.
Russian Federation
A. M. Platova
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical SciencesRussian Federation
I. V. Visotzkaya
I.M. Sechenov Moscow Medical AcademyRussian Federation
E. S. Gershteyn
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical SciencesRussian Federation
V. P. Letyagin
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical SciencesRussian Federation
N. E. Kushlinskiy
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical SciencesRussian Federation
E. E. Mironova
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical SciencesRussian Federation
References
Supplementary files
